Partner news
News
Partner news
FDA Clearance Brings RefleXion Closer to Expanding Cancer Treatment Market
Read full storyOther news
Third Pole Therapeutics Announces Inhaled Nitric Oxide Strategic Collaboration with Actelion, a Janssen Pharmaceutical Company of Johnson & Johnson
Read full storyJNJ Press releases
Big Pharma’s Billion-Dollar Scramble to Invest in Start-ups to Fuel Innovation
Read full storyPartner news
Protagonist Therapeutics Discontinues Phase 2b PROPEL Trial of PTG-100 for the Treatment of Ulcerative Colitis following Interim Analysis
Read full storyJNJ Press releases
Helsinn Group announces agreement to acquire worldwide rights to Valchlor®/Ledaga® - an approved and marketed alkylating agent for the topical treatment of mycosis fungoides‐type cutaneous T‐cell lymphoma, a rare type of skin cancer
Read full storyIn the media
What J&J gets out of JLABS incubators
Read full storyIn the media
Special Report Mental health: Brain scans and DNA tests personalise mental healthcare
Read full storyJNJ Press releases
Johnson & Johnson Innovation Launches Advancing the Safe Use of Healthcare Products QuickFire Challenge
Read full storyJNJ Press releases
Johnson & Johnson Innovation launches Singapore QuickFire Challenge Competition in collaboration with ETPL and SMART to accelerate solutions for diabetes and other metabolic diseases
Read full storyPartner news
Bristol-Myers Squibb to Acquire Padlock Therapeutics, Inc.
Read full storyJNJ Press releases
Johnson & Johnson Innovation Launches a New Company Incubation Model Located at the Janssen Research & Development Campus in Beerse, Belgium
Read full storyJNJ Press releases
Bioqube ventures launches specialist investment firm and announces collaboration with Johnson & Johnson Innovation, JLINX
Read full storyJNJ Press releases
Johnson & Johnson Innovation Launches JLINX: A New Company Incubation Model Located at the Janssen Campus in Belgium
Read full storyJNJ Press releases